Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice

To study antibody-mediated protection against Escherichia coli peritonitis in BALB/c mice, monoclonal antibodies (MAbs) were generated against the capsule (K5) and the lipopolysaccharide (O18) of E. coli. Flow cytometric analysis with two selected immunoglobulin M MAbs revealed that bacteria were antigenically heterogeneous. Arbitrarily, three subpopulations in E. coli O18K5 cultures could be distinguished by double immunofluorescence. A subpopulation bound only the anti-K5 MAb, and another subpopulation bound only the anti-O18 MAb. An intermediate subpopulation, however, bound both MAbs. In agreement with this result, combinations of both MAbs enhanced phagocytosis of fluorescein isothiocyanate-labeled bacteria by human polymorphonuclear leukocytes and mouse macrophage J774 cells as well. In protection experiments, combinations of both MAbs, preincubated with 3 50% lethal doses of E. coli O18K5, protected all mice upon intraperitoneal challenge. Relatively high doses of either MAb alone proved to be not fully protective in this infection model. Protection of mice by the combination of MAbs was associated with significantly lower (P < 0.02) tumor necrosis factor levels in serum 90 min after challenge compared with any other treatment group. Similarly, prophylactic administration of MAbs yielded significantly lower (P < 0.01) tumor necrosis factor levels in mice that received the combination of MAbs than in any other treatment group.

[1]  A. Algra,et al.  Escherichia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains , 1993, Journal of clinical microbiology.

[2]  V. Gant,et al.  The application of flow cytometry to the study of bacterial responses to antibiotics. , 1993, Journal of medical microbiology.

[3]  S. Opal,et al.  Choice of bacteria in animal models of sepsis , 1993, Infection and immunity.

[4]  A. Cross,et al.  Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection , 1993, Infection and immunity.

[5]  J. Verhoef,et al.  Monoclonal antibodies that detect live salmonellae , 1992, Applied and environmental microbiology.

[6]  N. Koles,et al.  Lipopolysaccharide heterogeneity in Escherichia coli J5 variants: analysis by flow cytometry. , 1992, The Journal of infectious diseases.

[7]  K. Jann,et al.  Capsules of Escherichia coli, expression and biological significance. , 1992, Canadian journal of microbiology.

[8]  M. A. Martin,et al.  Antiendotoxin monoclonal antibodies for gram-negative sepsis: guidelines from the IDSA. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Tarleton,et al.  Medium-scale production and purification of monoclonal antibodies in protein-free medium. , 1991, BioTechniques.

[10]  I. Mitov,et al.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid a of bacterial lipopolysaccharides , 1991, Infection.

[11]  C. Sprung,et al.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .

[12]  P. Ward,et al.  Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. , 1991, The Journal of infectious diseases.

[13]  I. Phillips,et al.  Bacteremia due to Escherichia coli: a study of 861 episodes. , 1990, Reviews of infectious diseases.

[14]  W. Neill,et al.  A comparison of immunoblotting, flow cytometry and ELISA to monitor the binding of anti-lipopolysaccharide monoclonal antibodies. , 1990, Journal of immunological methods.

[15]  J. Chia,et al.  Fluorescence-activated cell sorter analysis of binding by lipopolysaccharide-specific monoclonal antibodies to gram-negative bacteria. , 1990, The Journal of infectious diseases.

[16]  G. Pluschke,et al.  Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection. , 1989, Immunology.

[17]  A. Cross,et al.  Quantitative Relationship between Capsular Content and Killing of K1-Encapsulated Escherichia coli , 1989, Infection and immunity.

[18]  P. Courtoy,et al.  Staphylococcus aureus phagocytosis. A new cytofluorometric method using FITC and paraformaldehyde. , 1989, Journal of immunological methods.

[19]  A. Halstensen,et al.  Flow cytometric assay for the measurement of serum opsonins to Neisseria meningitidis serogroup B, serotype 15. , 1989, Journal of immunological methods.

[20]  R. Wenzel,et al.  The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? , 1988, International journal of epidemiology.

[21]  A P Phillips,et al.  Limitations of flow cytometry for the specific detection of bacteria in mixed populations. , 1988, Journal of immunological methods.

[22]  A. Cross,et al.  Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli. , 1986, The Journal of infectious diseases.

[23]  M. Achtman,et al.  Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1 , 1985, Infection and immunity.

[24]  K. Jann,et al.  Escherichia coli O18ac antigen: structure of the O-specific polysaccharide moiety , 1984, Infection and immunity.

[25]  A. Cross,et al.  The importance of the K1 capsule in invasive infections caused by Escherichia coli. , 1984, The Journal of infectious diseases.

[26]  M. Achtman,et al.  Role of the capsule and the O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing , 1983, Infection and immunity.

[27]  O. Laerum,et al.  Phagocytosis of Bacteria by Human Leukocytes Measured by Flow Cytometry , 1983, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[28]  W. R. Mccabe,et al.  Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. , 1978, The Journal of infectious diseases.

[29]  P. Ralph,et al.  Phagocytosis and cytolysis by a macrophage tumour and its cloned cell line , 1975, Nature.

[30]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[31]  S. Opal,et al.  The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. , 1993, The Journal of infectious diseases.

[32]  K. Jann,et al.  Structure and biosynthesis of the capsular antigens of Escherichia coli. , 1990, Current topics in microbiology and immunology.

[33]  A. Cross,et al.  Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. , 1988, The Journal of infectious diseases.

[34]  A. Cross,et al.  Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. , 1983, The Journal of infectious diseases.